These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 32939194)

  • 81. Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors.
    Benešová M; Bauder-Wüst U; Schäfer M; Klika KD; Mier W; Haberkorn U; Kopka K; Eder M
    J Med Chem; 2016 Mar; 59(5):1761-75. PubMed ID: 26878194
    [TBL] [Abstract][Full Text] [Related]  

  • 82. (68)Ga-PSMA PET/CT imaging in primary hepatocellular carcinoma.
    Sasikumar A; Joy A; Nanabala R; Pillai MR; Thomas B; Vikraman KR
    Eur J Nucl Med Mol Imaging; 2016 Apr; 43(4):795-6. PubMed ID: 26743897
    [No Abstract]   [Full Text] [Related]  

  • 83. PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status.
    Lütje S; Heskamp S; Cornelissen AS; Poeppel TD; van den Broek SA; Rosenbaum-Krumme S; Bockisch A; Gotthardt M; Rijpkema M; Boerman OC
    Theranostics; 2015; 5(12):1388-401. PubMed ID: 26681984
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Indium-111 Capromab Pendetide (ProstaScint(®)) Demonstrates Renal Cell Carcinoma and Aortocaval Nodal Metastases from Prostate Adenocarcinoma.
    Rizvi T; Deng C; Rehm PK
    World J Nucl Med; 2015; 14(3):209-11. PubMed ID: 26420994
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Development of a Single Vial Kit Solution for Radiolabeling of 68Ga-DKFZ-PSMA-11 and Its Performance in Prostate Cancer Patients.
    Ebenhan T; Vorster M; Marjanovic-Painter B; Wagener J; Suthiram J; Modiselle M; Mokaleng B; Zeevaart JR; Sathekge M
    Molecules; 2015 Aug; 20(8):14860-78. PubMed ID: 26287143
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
    Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M
    J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Evaluation of Hybrid ⁶⁸Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy.
    Eiber M; Maurer T; Souvatzoglou M; Beer AJ; Ruffani A; Haller B; Graner FP; Kübler H; Haberkorn U; Eisenhut M; Wester HJ; Gschwend JE; Schwaiger M
    J Nucl Med; 2015 May; 56(5):668-74. PubMed ID: 25791990
    [TBL] [Abstract][Full Text] [Related]  

  • 88. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.
    Afshar-Oromieh A; Avtzi E; Giesel FL; Holland-Letz T; Linhart HG; Eder M; Eisenhut M; Boxler S; Hadaschik BA; Kratochwil C; Weichert W; Kopka K; Debus J; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2015 Feb; 42(2):197-209. PubMed ID: 25411132
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer.
    Eder M; Neels O; Müller M; Bauder-Wüst U; Remde Y; Schäfer M; Hennrich U; Eisenhut M; Afshar-Oromieh A; Haberkorn U; Kopka K
    Pharmaceuticals (Basel); 2014 Jun; 7(7):779-96. PubMed ID: 24983957
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy.
    Zechmann CM; Afshar-Oromieh A; Armor T; Stubbs JB; Mier W; Hadaschik B; Joyal J; Kopka K; Debus J; Babich JW; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1280-92. PubMed ID: 24577951
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Meta-analysis of (11)C-choline and (18)F-choline PET/CT for management of patients with prostate cancer.
    von Eyben FE; Kairemo K
    Nucl Med Commun; 2014 Mar; 35(3):221-30. PubMed ID: 24240194
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer.
    Afshar-Oromieh A; Zechmann CM; Malcher A; Eder M; Eisenhut M; Linhart HG; Holland-Letz T; Hadaschik BA; Giesel FL; Debus J; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2014 Jan; 41(1):11-20. PubMed ID: 24072344
    [TBL] [Abstract][Full Text] [Related]  

  • 93. PET imaging in prostate cancer: focus on prostate-specific membrane antigen.
    Mease RC; Foss CA; Pomper MG
    Curr Top Med Chem; 2013; 13(8):951-62. PubMed ID: 23590171
    [TBL] [Abstract][Full Text] [Related]  

  • 94. A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer.
    Schäfer M; Bauder-Wüst U; Leotta K; Zoller F; Mier W; Haberkorn U; Eisenhut M; Eder M
    EJNMMI Res; 2012 Jun; 2(1):23. PubMed ID: 22673157
    [TBL] [Abstract][Full Text] [Related]  

  • 95. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging.
    Eder M; Schäfer M; Bauder-Wüst U; Hull WE; Wängler C; Mier W; Haberkorn U; Eisenhut M
    Bioconjug Chem; 2012 Apr; 23(4):688-97. PubMed ID: 22369515
    [TBL] [Abstract][Full Text] [Related]  

  • 96. [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH.
    Afshar-Oromieh A; Haberkorn U; Eder M; Eisenhut M; Zechmann CM
    Eur J Nucl Med Mol Imaging; 2012 Jun; 39(6):1085-6. PubMed ID: 22310854
    [No Abstract]   [Full Text] [Related]  

  • 97. Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer.
    Bařinka C; Rojas C; Slusher B; Pomper M
    Curr Med Chem; 2012; 19(6):856-70. PubMed ID: 22214450
    [TBL] [Abstract][Full Text] [Related]  

  • 98. 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer.
    Banerjee SR; Pullambhatla M; Byun Y; Nimmagadda S; Green G; Fox JJ; Horti A; Mease RC; Pomper MG
    J Med Chem; 2010 Jul; 53(14):5333-41. PubMed ID: 20568777
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.
    Hillier SM; Maresca KP; Femia FJ; Marquis JC; Foss CA; Nguyen N; Zimmerman CN; Barrett JA; Eckelman WC; Pomper MG; Joyal JL; Babich JW
    Cancer Res; 2009 Sep; 69(17):6932-40. PubMed ID: 19706750
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Novel role of prostate-specific membrane antigen in suppressing prostate cancer invasiveness.
    Ghosh A; Wang X; Klein E; Heston WD
    Cancer Res; 2005 Feb; 65(3):727-31. PubMed ID: 15705868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.